Market & Regulation
Anthropic Ventures into Drug Development
The Verge AIhigh confidence
Why it matters
- →Anthropic's move into drug development signals a new direction for AI companies beyond providing tools.
- →The initiative could accelerate the discovery of treatments for neglected diseases using AI.
- →The complexity of drug approval processes highlights the challenges AI faces in transforming drug development.
Anthropic has announced its entry into drug development with the launch of Claude Science, an AI platform aimed at accelerating scientific discovery. The company plans to develop its own drugs, targeting neglected diseases, which sets it apart from other AI firms that primarily provide tools to the pharmaceutical industry. Despite the potential of AI in drug discovery, experts caution that the process of bringing AI-designed drugs to market is lengthy and requires significant real-world testing. Anthropic's move highlights the growing intersection of AI and life sciences, though the impact remains to be seen.
Read originalThe story around this
Earlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
More from The Verge AI
More in Market & Regulation
© TechCrunch AIMarket & Regulationbusiness
Crusoe cancels $1.25B Boom turbine deal
The collapse of Crusoe’s $1.25 billion order for Boom Supersonic’s stationary turbines exposes the fragility of AI infrastructure financing. While Crusoe raised $3.9 billion, it pivoted away from on-site gas generation, opting instead for grid power and diverse energy mixes. This signals that even well-funded data center operators are prioritizing flexibility over massive, long-term capital commitments to specialized hardware. Boom’s pivot to sell jet engines as power plants was a bold bet on AI energy needs, but losing its anchor customer suggests the market is more cautious than anticipated.
TechCrunch AI
© TechCrunch AI
